Epigenetic Reprogramming of the Type III Interferon Response Potentiates Antiviral Activity and Suppresses Tumor Growth

PLoS Biology

Volumn 12, Issue 1, 2014, Pages

  Ding, Siyuan ^a   Khoury Hanold, William ^a   Iwasaki, Akiko ^a   Robek, Michael D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; CRICETINAE; CYTOMEGALOVIRUS; DNA METHYLATION; EPIGENESIS, GENETIC; HEPATOCYTES; HERPESVIRUS 1, HUMAN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-GAMMA; MICE; NIH 3T3 CELLS; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOKINE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VESICULOVIRUS;

EID: 84893733987     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001758     Document Type: Article

References (34)

1. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77.
2. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-68.
3. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, et al. (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80: 4501-4509.
4. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, et al. (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898.
5. Robek MD, Boyd BS, Chisari FV, (2005) Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79: 3851-3854.
6. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, et al. (2008) Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4: e1000151 doi: 10.1371/journal.ppat.1000151.
7. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, et al. (2010) Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 84: 5670-5677.
8. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, et al. (2011) IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 108: 7944-7949.
9. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
10. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
11. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
12. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
13. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, et al. (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906.
14. Pagliaccetti NE, Robek MD, (2010) Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. J Interferon Cytokine Res 30: 585-590.
15. Sommereyns C, Paul S, Staeheli P, Michiels T, (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017 doi: 10.1371/journal.ppat.1000017.
16. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, et al. (2009) Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 10: 702-714.
17. Jones PA, (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 484-492.
18. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163.
19. Nardini M, Gnesutta N, Donati G, Gatta R, Forni C, et al. (2013) Sequence-specific transcription factor NF-Y displays histone-like DNA binding and H2B-like ubiquitination. Cell 152: 132-143.
20. Kim CG, Sheffery M, (1990) Physical characterization of the purified CCAAT transcription factor, alpha-CP1. J Biol Chem 265: 13362-13369.
21. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM, (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 119-134.
22. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, et al. (2006) Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66: 4468-4477.
23. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, et al. (2007) IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 178: 5086-5098.
24. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T, (2006) Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176: 7686-7694.
25. Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, et al. (2006) The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci U S A 103: 1587-1592.
26. Baylin SB, Jones PA, (2011) A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 11: 726-734.
27. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, et al. (2012) Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol 189: 3759-3766.
28. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454.
29. Parato KA, Senger D, Forsyth PA, Bell JC, (2005) Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976.
30. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, et al. (2007) Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109: 2781-2790.
31. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R, (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247-1252.
32. Smith KT, Workman JL, (2009) Histone deacetylase inhibitors: anticancer compounds. Int J Biochem Cell Biol 41: 21-25.
33. Glozak MA, Seto E, (2007) Histone deacetylases and cancer. Oncogene 26: 5420-5432.
34. Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM, (2009) Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 29: 5171-5184.